Desensitization to imatinib in patients with leukemia

Annals of Allergy, Asthma and Immunology

Volumn 97, Issue 2, 2006, Pages 216-222

  Nelson Jr , Robert P ^a,b   Cornetta, Kenneth ^a   Ward, Kelly E ^a   Ramanuja, Srinivasan ^a   Fausel, Chris ^a   Cripe, Larry D ^a  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CALCIUM; CEFTRIAXONE; CYTARABINE; DIPHENHYDRAMINE; DIURETIC AGENT; GLUCOCORTICOID; HYDROXYUREA; IMATINIB; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; PSORALEN; RAPAMYCIN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ANASARCA; ARTHRALGIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; DESENSITIZATION; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HYPERSENSITIVITY; FACE EDEMA; FATIGUE; FEMALE; FEVER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEG EDEMA; LEUKEMIA; MALE; MUSCLE CRAMP; MYALGIA; NIGHT SWEAT; PERIORBITAL EDEMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PRURITUS; RASH; SKIN TEST; TABLET FORMULATION; THROAT DISEASE; TREATMENT OUTCOME; URTICARIA;

EID: 33747646206     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60016-6     Document Type: Article

References (40)

1. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100-104.
2. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
3. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691-3698.
4. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis. 1997;23:380-394.
5. Mauro MJ, Druker BJ. ST1571: a gene product-targeted therapy for leukemia. Curr Oncol Rep. 2001;3:223-227.
6. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
7. O'Dwyer ME, Druker BJ. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer. Curr Cancer Drug Targets. 2001;1:49-57.
8. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002;26:881-884.
9. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
10. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
11. Brouard MC, Prins C, Mach-Pascual S, Saurat JH. Acute generalzed exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology. 2001;203:57-59.
12. Rule SA, O'Brien SG, Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood. 2002;100:3434-3435.
13. Tanvetyanon T, Nand S. Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing. Ann Pharmacologyther. 2003;37:1818-1820.
14. Park MA, Volcheck GW, Guarderas JC. Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature. Allergy Asthma Proc. 2004;25:345-347.
15. Schamun A, Bullorsky E, Stemmelin G, Saxton R, Ricchione D. Treatment with cyclosporin A cream for the cutaneous reactions associated with imatinib therapy. Blood. 2005;105:2996-2997.
16. Wendel GD Jr, Stark BJ, Jamison RB, Molina RD, Sullivan TJ. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med. 1985;312:1229-1232.
17. Hughes TE, Almgren JD, McGuffin RW, Omoto RJ. Cotrimoxaxole desensitization in bone marrow transplantation. Ann Intern Med. 1986;105:148.
18. Smith RM, Iwamoto GK, Richerson HB, Flaherty JP. Trimethoprim- sulfamethoxazole desensitization in the acquired immunodeficiency syndrome. Ann Intern Med. 1987;106:335.
19. Matz I, Borish LC, Routes JM, Rosenwasser LJ. Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Respir Crit Care Med. 1994;149(3 pt 1):815-817.
20. Dominguez Ortega J, Robledo T, Martinez-Cocera C, et al. Desensitization to azanthioprine. J Investig Allergol Clin Immunol 1999;9:337-338.
21. White MV, Haddad ZH, Brunner E, Sainz C. Desensitization to trimethoprim sulfamethoxazole in patients with acquired immune deficiency syndrome and Pneumocystis carinii pneumonia. Ann Allergy. 1989;62:177-179.
22. Dreborg S. Skin tests used in type I allergy testing. Allergy. 1989;44(suppl 10):1-59.
23. Turkeltaub P. In vivo standardization. In: Middleton E Jr, Ellis EF, Adkinson NJ Jr, Yunginger JW, ed. Allergy: Principles and Practice. 3rd ed. St Louis, MO: CV Mosby Co; 1988:388-401.
24. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
25. Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med. 2001;345:618-619.
26. Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. 2002;95:881-887.
27. Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol. 2002;117:620-622.
28. Konstantopoulos K, Papadogianni A, Dimopoulou M, Kourelis C, Meletis J. Pityriasis rosea associated with imatinib (STI571, Gleevec). Dermatology. 2002;205:172-173.
29. Lim DS, Muir J. Oral lichenoid reaction to imatinib (STI571, Gleevec). Dermatology. 2002;205:169-171.
30. Drummond A, Micallef-Eynaud P, Douglas WS, Hay I, Holyoake TL, Drummond MW. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol. 2003;120:911-913.
31. Rousselot P, Larghero J, Raffoux E, et al. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate. Br J Haematol. 2003;120:1091-1092.
32. Schaich M, Schakel K, Illmer T, Ehninger G, Bornhauser M. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2003;82:303-304.
33. Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003;48:201-206.
34. Breccia M, Latagliata R, Carmosino I, Mandelli F, Alimena G. Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia. Leukemia. 2004;18:182.
35. Ena P, Chiarolini F, Siddi GM, Cossu A. Oral lichenoid eruption secondary to imatinib (Glivec). J Dermatol Treat. 2004;15:253-255.
36. Esmaeli B, Diba R, Ahmadi MA, et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye. 2004;18:760-762.
37. Grossman WJ, Wilson DB. Hypopigmentation from imatinib mesylate (Gleevec). J Pediatr Hematol Oncol. 2004;26:214.
38. Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol. 2005;74:121-123.
39. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med. 2003;139:683-693.
40. Caumes E, Guermonprez G, Winter C, Katlama C, Bricaire F. A life-threatening adverse reaction during trimethoprim-sulfamethoxazole desensitization in a previously hypersensitive patient infected with human immunodeficiency virus. Clin Infect Dis. 1996;23:1313-1314.